title: The response to beta-agonists in wheezy infants: three methods compared.
abstract: BACKGROUND
  Studies into the effects of salbutamol in the treatment of wheeze in infancy have been conflicting, possibly due to differences in outcome variables. We aimed to assess the response to salbutamol using indices derived from passive and forced expiration.
  
  
  METHODS
  We recruited 39 infants who had a history of wheezing (mean age 43 weeks) and measured maximum flow at functional residual capacity (V'(max FRC)) by rapid thoracoabdominal compression (RTC), and forced expired volume at 0.4s (FEV0.4) using the raised-volume RTC technique (RV-RTC). We calculated passive compliance (C(rs)), resistance (R(rs)) and time constant (tau) from relaxed expirations that followed the augmented inspirations delivered during RV-RTC. Measurements were repeated after aerosol salbutamol (800 mcg).
  
  
  RESULTS
  Data were obtained in 32 infants for V'(max FRC), 22 for FEV0.4 and 19 for passive mechanics. There were no mean changes in any index of forced expiration after salbutamol. Some individuals showed significant changes (improvement or worsening) in one or other index. Overall, there was a small increase in C(rs) after salbutamol but no change in R(rs) or tau.
  
  
  CONCLUSIONS
  We found no consistent pattern of response in either index of forced expiration. Validated clinical scores or alternative physiological techniques may be preferable to respiratory mechanics in assessing bronchodilator response.
authors.affiliation: Department of Child Health, Institute for Lung Health, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, P.O. Box 65, Leicester LE2 7LX, UK. csb@le.ac.uk
authors.forename: Caroline S
authors.initials: CS
authors.lastname: Beardsmore
authors.forename: Catherine
authors.initials: C
authors.lastname: Page
authors.forename: Michael
authors.initials: M
authors.lastname: Silverman
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000420:Albuterol / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007223:Infant; D015656:Respiratory Mechanics / Q000187:drug effects; D012135:Respiratory Sounds / Q000187:drug effects* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D000420:Albuterol